Background Long-term exposure to high levels of fatty acids impairs insulin secretion and exaggerates glucagon secretion. The aim of this study was to explore if the antihyperglycemic agent, Isosteviol (ISV), is able to counteract palmitate-induced α-cell dysfunction and to influence α-cell gene expression. Methodology/Principal Findings Long-term incubation studies with clonal α-TC1–6 cells were performed in the presence of 0.5 mM palmitate with or without ISV. We investigated effects on glucagon secretion, glucagon content, cellular triglyceride (TG) content, cell proliferation, and expression of genes involved in controlling glucagon synthesis, fatty acid metabolism, and insulin signal transduction. Furthermore, we studied effects of ISV on palmitate-induced glucagon secretion from isolated mouse islets. Culturing α-cells for 72-h with 0.5 mM palmitate in the presence of 18 mM glucose resulted in a 56% (p<0.01) increase in glucagon secretion. Concomitantly, the TG content of α-cells increased by 78% (p<0.01) and cell proliferation decreased by 19% (p<0.05). At 18 mM glucose, ISV (10？8 and 10？6 M) reduced palmitate-stimulated glucagon release by 27% (p<0.05) and 27% (p<0.05), respectively. ISV (10？6 M) also counteracted the palmitate-induced hypersecretion of glucagon in mouse islets. ISV (10？6 M) reduced α-TC1–6 cell proliferation rate by 25% (p<0.05), but ISV (10？8 and 10？6 M) had no effect on TG content in the presence of palmitate. Palmitate (0.5 mM) increased Pcsk2 (p<0.001), Irs2 (p<0.001), Fasn (p<0.001), Srebf2 (p<0.001), Acaca (p<0.01), Pax6 (p<0.05) and Gcg mRNA expression (p<0.05). ISV significantly (p<0.05) up-regulated Insr, Irs1, Irs2, Pik3r1 and Akt1 gene expression in the presence of palmitate. Conclusions/Significance ISV counteracts α-cell hypersecretion and apparently contributes to changes in expression of key genes resulting from long-term exposure to palmitate. ISV apparently acts as a glucagonostatic drug with potential as a new anti-diabetic drug for the treatment of type 2 diabetes.
References
[1]
Unger RH, Orci L (1975) The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1: 14–16.
[2]
Dunning BE, Gerich JE (2007) The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 28: 253–283.
[3]
Unger RH, Orci L (1977) The role of glucagon in the endogenous hyperglycemia of diabetes mellitus. Annu Rev Med 28: 119–130.
[4]
Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB (1987) Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64: 106–110.
[5]
Baron AD, Schaeffer L, Shragg P, Kolterman OG (1987) Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 36: 274–283.
[6]
Belfort R, Mandarino L, Kashyap S, Wirfel K, Pratipanawatr T, et al. (2005) Dose-response effect of elevated plasma free fatty acid on insulin signaling. Diabetes 54: 1640–1648.
[7]
Randle PJ, Garland PB, Hales CN, Newsholme EA (1963) The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1: 785–789.
[8]
Boden G, Laakso M (2004) Lipids and glucose in type 2 diabetes: what is the cause and effect? Diabetes Care 27: 2253–2259.
[9]
Olofsson CS, Salehi A, Gopel SO, Holm C, Rorsman P (2004) Palmitate stimulation of glucagon secretion in mouse pancreatic alpha-cells results from activation of L-type calcium channels and elevation of cytoplasmic calcium. Diabetes 53: 2836–2843.
[10]
Bollheimer LC, Landauer HC, Troll S, Schweimer J, Wrede CE, et al. (2004) Stimulatory short-term effects of free fatty acids on glucagon secretion at low to normal glucose concentrations. Metabolism 53: 1443–1448.
[11]
Hong J, Abudula R, Chen J, Jeppesen PB, Dyrskog SE, et al. (2005) The short-term effect of fatty acids on glucagon secretion is influenced by their chain length, spatial configuration, and degree of unsaturation: studies in vitro. Metabolism 54: 1329–1336.
[12]
Hong J, Jeppesen PB, Nordentoft I, Hermansen K (2007) Fatty acid-induced effect on glucagon secretion is mediated via fatty acid oxidation. Diabetes Metab Res Rev 23: 202–210.
[13]
Gremlich S, Bonny C, Waeber G, Thorens B (1997) Fatty acids decrease IDX-1 expression in rat pancreatic islets and reduce GLUT2, glucokinase, insulin, and somatostatin levels. J Biol Chem 272: 30261–30269.
[14]
Gromada J, Franklin I, Wollheim CB (2007) Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 28: 84–116.
[15]
Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, et al. (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 741–744.
[16]
Tahrani AA, Bailey CJ, Del PS, Barnett AH (2011) Management of type 2 diabetes: new and future developments in treatment. Lancet 378: 182–197.
[17]
Hong J, Chen L, Jeppesen PB, Nordentoft I, Hermansen K (2006) Stevioside counteracts the alpha-cell hypersecretion caused by long-term palmitate exposure. Am J Physiol Endocrinol Metab 290: E416–E422.
[18]
Nordentoft I, Jeppesen PB, Hong J, Abudula R, Hermansen K (2008) Isosteviol increases insulin sensitivity and changes gene expression of key insulin regulatory genes and transcription factors in islets of the diabetic KKAy mouse. Diabetes Obes Metab 10: 939–949.
[19]
Chen J, Jeppesen PB, Nordentoft I, Hermansen K (2006) Stevioside Counteracts Beta-Cell Lipotoxicity without Affecting Acetyl CoA Carboxylase. Rev Diabet Stud 3: 178–188.
[20]
Gregersen S, Jeppesen PB, Holst JJ, Hermansen K (2004) Antihyperglycemic effects of stevioside in type 2 diabetic subjects. Metabolism 53: 73–76.
[21]
Jeppesen PB, Gregersen S, Rolfsen SE, Jepsen M, Colombo M, et al. (2003) Antihyperglycemic and blood pressure-reducing effects of stevioside in the diabetic Goto-Kakizaki rat. Metabolism 52: 372–378.
[22]
Jeppesen PB, Gregersen S, Alstrup KK, Hermansen K (2002) Stevioside induces antihyperglycaemic, insulinotropic and glucagonostatic effects in vivo: studies in the diabetic Goto-Kakizaki (GK) rats. Phytomedicine 9: 9–14.
[23]
Bansal P, Wang Q (2008) Insulin as a physiological modulator of glucagon secretion. Am J Physiol Endocrinol Metab 295: E751–E761.
[24]
Franklin I, Gromada J, Gjinovci A, Theander S, Wollheim CB (2005) Beta-cell secretory products activate alpha-cell ATP-dependent potassium channels to inhibit glucagon release. Diabetes 54: 1808–1815.
[25]
Ravier MA, Rutter GA (2005) Glucose or insulin, but not zinc ions, inhibit glucagon secretion from mouse pancreatic alpha-cells. Diabetes 54: 1789–1797.
[26]
Asplin CM, Paquette TL, Palmer JP (1981) In vivo inhibition of glucagon secretion by paracrine beta cell activity in man. J Clin Invest 68: 314–318.
[27]
Unger RH, Orci L (2010) Paracrinology of islets and the paracrinopathy of diabetes. Proc Natl Acad Sci U S A 107: 16009–16012.
[28]
Leung YM, Ahmed I, Sheu L, Gao X, Hara M, et al. (2006) Insulin regulates islet alpha-cell function by reducing KATP channel sensitivity to adenosine 5′-triphosphate inhibition. Endocrinology 147: 2155–2162.
[29]
Xu E, Kumar M, Zhang Y, Ju W, Obata T, et al. (2006) Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system. Cell Metab 3: 47–58.
[30]
Paranjape SA, Chan O, Zhu W, Horblitt AM, McNay EC, et al. (2010) Influence of insulin in the ventromedial hypothalamus on pancreatic glucagon secretion in vivo. Diabetes 59: 1521–1527.
[31]
Hamaguchi K, Leiter EH (1990) Comparison of cytokine effects on mouse pancreatic alpha-cell and beta-cell lines. Viability, secretory function, and MHC antigen expression. Diabetes 39: 415–425.
[32]
Kisanuki K, Kishikawa H, Araki E, Shirotani T, Uehara M, et al. (1995) Expression of insulin receptor on clonal pancreatic alpha cells and its possible role for insulin-stimulated negative regulation of glucagon secretion. Diabetologia 38: 422–429.
[33]
Kawamori D, Kurpad AJ, Hu J, Liew CW, Shih JL, et al. (2009) Insulin signaling in alpha cells modulates glucagon secretion in vivo. Cell Metab 9: 350–361.
Gromada J, Duttaroy A, Rorsman P (2009) The insulin receptor talks to glucagon? Cell Metab 9: 303–305.
[36]
Gonzalez M, Boer U, Dickel C, Quentin T, Cierny I, et al. (2008) Loss of insulin-induced inhibition of glucagon gene transcription in hamster pancreatic islet alpha cells by long-term insulin exposure. Diabetologia 51: 2012–2021.
[37]
Rothenberg PL, Willison LD, Simon J, Wolf BA (1995) Glucose-induced insulin receptor tyrosine phosphorylation in insulin-secreting beta-cells. Diabetes 44: 802–809.
[38]
Piro S, Maniscalchi ET, Monello A, Pandini G, Mascali LG, et al. (2010) Palmitate affects insulin receptor phosphorylation and intracellular insulin signal in a pancreatic alpha-cell line. Endocrinology 151: 4197–4206.
[39]
Kaneko K, Shirotani T, Araki E, Matsumoto K, Taguchi T, et al. (1999) Insulin inhibits glucagon secretion by the activation of PI3-kinase in In-R1-G9 cells. Diabetes Res Clin Pract 44: 83–92.
[40]
Rouille Y, Westermark G, Martin SK, Steiner DF (1994) Proglucagon is processed to glucagon by prohormone convertase PC2 in alpha TC1–6 cells. Proc Natl Acad Sci U S A 91: 3242–3246.
[41]
Furuta M, Zhou A, Webb G, Carroll R, Ravazzola M, et al. (2001) Severe defect in proglucagon processing in islet A-cells of prohormone convertase 2 null mice. J Biol Chem 276: 27197–27202.
[42]
Gosmain Y, Marthinet E, Cheyssac C, Guerardel A, Mamin A, et al. (2010) Pax6 controls the expression of critical genes involved in pancreatic {alpha} cell differentiation and function. J Biol Chem 285: 33381–33393.
[43]
Katz LS, Gosmain Y, Marthinet E, Philippe J (2009) Pax6 regulates the proglucagon processing enzyme PC2 and its chaperone 7B2. Mol Cell Biol 29: 2322–2334.
[44]
Liu Z, Kim W, Chen Z, Shin YK, Carlson OD, et al. (2011) Insulin and glucagon regulate pancreatic alpha-cell proliferation. PLoS One 6: e16096.
[45]
Mizushina Y, Akihisa T, Ukiya M, Hamasaki Y, Murakami-Nakai C, et al. (2005) Structural analysis of isosteviol and related compounds as DNA polymerase and DNA topoisomerase inhibitors. Life Sci 77: 2127–2140.
[46]
Jeppesen PB, Gregersen S, Poulsen CR, Hermansen K (2000) Stevioside acts directly on pancreatic beta cells to secrete insulin: actions independent of cyclic adenosine monophosphate and adenosine triphosphate-sensitive K+-channel activity. Metabolism 49: 208–214.
[47]
Xiao J, Gregersen S, Pedersen SB, Hermansen K (2002) Differential impact of acute and chronic lipotoxicity on gene expression in INS-1 cells. Metabolism 51: 155–162.
[48]
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402–408.
